Jonathan Gootenberg draws from fundamental biological insights to engineer new molecular
tools. These technologies, including CRISPR-mediated genome and transcriptome perturbation and non-destructive cellular sensing, allow for unprecedented manipulation and profiling of cellular states in the body, and have multiple applications in basic science, diagnostics, and therapeutics. These technologies have been translated into multiple biotechnology companies, including 5 companies that Dr. Gootenberg has co-founded
Dr. Gootenberg earned his bachelor’s degree in mathematics and biological engineering at MIT.
He received his PhD in Systems Biology from Harvard University, during which he conducted
research with Aviv Regev and Feng Zhang at the McGovern Institute and Broad Institute of MIT
and Harvard. He is one of the first members of the McGovern Institute Fellows program, which
supports the transition to independent research for exceptional recent PhD graduates. He
has been recognized with awards including Forbes 30 under 30, Technology Review 35 under
35, Business Insider 30 and under, Endpoints 20 under 40, and as an inaugural Termeer Foundation scholar.